AQR Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$76M Buy
171,031
+27,380
+19% +$12.8M 0.03% 597
2025
Q4
$65.1M Sell
143,651
-18,032
-11% -$7.77M 0.03% 592
2025
Q3
$63.3M Buy
161,683
+20,147
+14% +$8.42M 0.04% 537
2025
Q2
$62.2M Sell
141,536
-4,335
-3% -$2M 0.05% 480
2025
Q1
$69.6M Sell
145,871
-99,914
-41% -$46.6M 0.07% 370
2024
Q4
$99M Sell
245,785
-235,076
-49% -$109M 0.13% 206
2024
Q3
$223M Sell
480,861
-55,253
-10% -$26.5M 0.31% 58
2024
Q2
$251M Sell
536,114
-130,577
-20% -$56.7M 0.39% 39
2024
Q1
$279M Buy
666,691
+21,923
+3% +$9.27M 0.47% 29
2023
Q4
$262M Buy
644,768
+1,271
+0.2% +$470K 0.49% 30
2023
Q3
$224M Buy
643,497
+31,067
+5% +$10.9M 0.46% 35
2023
Q2
$216M Buy
612,430
+40,915
+7% +$13.8M 0.46% 39
2023
Q1
$180M Sell
571,515
-16,079
-3% -$4.82M 0.4% 49
2022
Q4
$169M Buy
587,594
+93,063
+19% +$28.4M 0.38% 44
2022
Q3
$143M Sell
494,531
-22,253
-4% -$6.4M 0.35% 49
2022
Q2
$144M Buy
516,784
+16,840
+3% +$4.51M 0.33% 57
2022
Q1
$129M Sell
499,944
-98,539
-16% -$23.4M 0.24% 94
2021
Q4
$131M Sell
598,483
-40,834
-6% -$7.94M 0.24% 99
2021
Q3
$116M Sell
639,317
-67,436
-10% -$13.2M 0.22% 112
2021
Q2
$139M Sell
706,753
-203,774
-22% -$42.6M 0.24% 97
2021
Q1
$195M Buy
910,527
+350,146
+62% +$76.9M 0.32% 61
2020
Q4
$129M Sell
560,381
-83,887
-13% -$19.2M 0.23% 104
2020
Q3
$175M Buy
644,268
+32,453
+5% +$8.95M 0.3% 70
2020
Q2
$176M Buy
611,815
+16,945
+3% +$4.59M 0.28% 78
2020
Q1
$138M Buy
594,870
+184,560
+45% +$42.3M 0.23% 107
2019
Q4
$89.6M Buy
410,310
+138,186
+51% +$28M 0.1% 254
2019
Q3
$45.8M Buy
272,124
+22,158
+9% +$3.92M 0.05% 399
2019
Q2
$45M Sell
249,966
-194,184
-44% -$33.9M 0.05% 415
2019
Q1
$81M Sell
444,150
-314,883
-41% -$58.2M 0.09% 267
2018
Q4
$126M Sell
759,033
-522,311
-41% -$90.5M 0.15% 171
2018
Q3
$247M Buy
1,281,344
+449,549
+54% +$80M 0.24% 112
2018
Q2
$141M Sell
831,795
-432,617
-34% -$67.1M 0.14% 182
2018
Q1
$206M Sell
1,264,412
-253,423
-17% -$41.4M 0.22% 112
2017
Q4
$227M Sell
1,517,835
-372,855
-20% -$55.2M 0.24% 114
2017
Q3
$287M Buy
1,890,690
+1,046,806
+124% +$158M 0.34% 73
2017
Q2
$109M Buy
843,884
+601,942
+249% +$72.5M 0.14% 189
2017
Q1
$26.5M Buy
241,942
+124,781
+107% +$11M 0.04% 532
2016
Q4
$8.63M Buy
+117,161
New +$9.53M 0.01% 813
2016
Q1
Sell
-46,414
Closed -$5.84M 2287
2015
Q4
$5.84M Sell
46,414
-426,800
-90% -$51.5M 0.01% 872
2015
Q3
$49.3M Sell
473,214
-348,218
-42% -$44.7M 0.1% 270
2015
Q2
$101M Sell
821,432
-81,323
-9% -$10.2M 0.2% 140
2015
Q1
$106M Buy
902,755
+275,353
+44% +$33M 0.24% 118
2014
Q4
$74.5M Sell
627,402
-42,374
-6% -$4.77M 0.16% 184
2014
Q3
$75.2M Buy
669,776
+185,598
+38% +$17.7M 0.21% 131
2014
Q2
$45.8M Buy
484,178
+29,200
+6% +$2.05M 0.12% 218
2014
Q1
$32.2M Sell
454,978
-65,901
-13% -$5.22M 0.1% 253
2013
Q4
$38.7M Buy
520,879
+80,216
+18% +$5.59M 0.12% 231
2013
Q3
$33.4M Sell
440,663
-71,882
-14% -$5.72M 0.12% 226
2013
Q2
$40.9M Buy
+512,545
New +$37.7M 0.15% 179

Other funds holding VRTX

AQR Capital Management's VRTX Position: Q1 2026 in Review

AQR Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 19% in Q1 2026, buying an estimated $12.8M and bringing the position to 171,031 shares worth $76M. The position accounts for 0.03% of the portfolio, ranked #597.

AQR Capital Management first reported a position in VRTX in Q2 2013 and has held it in 49 quarters since. The position peaked at $287M in Q3 2017. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • AQR Capital Management held 171,031 shares of Vertex Pharmaceuticals worth $76M as of Q1 2026.
  • AQR Capital Management bought 27,380 Vertex Pharmaceuticals shares in Q1 2026, an estimated $12.8M.
  • Vertex Pharmaceuticals made up 0.03% of AQR Capital Management's portfolio in Q1 2026, its #597 holding.
  • AQR Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • AQR Capital Management's Vertex Pharmaceuticals position peaked at $287M in Q3 2017.
  • 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.